N
SER icon

Nuveen’s Serina Therapeutics SER Stock Holding History

Nuveen’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,741
Closed -$57K – 3381
2020
Q1 		$57K Sell
1,741
-64
-4% -$3.01K ﹤0.01% 3098
2019
Q4 		$115K Hold
1,805
– – ﹤0.01% 3122
2019
Q3 		$124K Buy
1,805
+313
+21% +$29.7K ﹤0.01% 3155
2019
Q2 		$192K Buy
+1,492
New +$202K ﹤0.01% 3180

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Nuveen's SER Position: Q2 2020 in Review

Nuveen sold out of Serina Therapeutics (SER) in Q2 2020, closing a stake of 1,741 shares — an estimated $57K sold.

Nuveen first reported a position in SER in Q2 2019 and held it in 4 quarters. The position peaked at $192K in Q2 2019. 48 funds tracked by Wall St. Rank hold SER as of Q2 2020.

  • Nuveen reported no remaining Serina Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Nuveen sold 1,741 Serina Therapeutics shares in Q2 2020, an estimated $57K.
  • Nuveen first reported a position in Serina Therapeutics in Q2 2019 and held it in 4 quarters.
  • Nuveen's Serina Therapeutics position peaked at $192K in Q2 2019.
  • 48 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2020.

Based on Nuveen's 13F filing for Q2 2020, filed 14 Aug 2020.